参考文献/References:
[1]Hirsch AT,Haskal ZJ,Hertzer NR,et al.ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity,renal,mesenteric,and abdominal aortic):a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery,Society for Cardiovascular Angiography and Interventions,Society for Vascular Medicine,Society of Interventional Radiology,and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) summary of recommendations.J Vasc Interv Radiol,2006,17(9):1383-1397.
[2]Norgren L,Hiatt WR,Dormandy JA,et al.for the TASC II Working Group.Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).J Vasc Surg,2007,45(Suppl S):S5-S67.
[3]Dick P,Sabeti S,Mlekusch W,et al.Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis:initial experience.Radiology,2008,248(1):297-302.
[4]Rocha-Singh KJ,Jaff MR,Crabtree TR,et al.for VIVA Physicians Inc.Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease.Catheter Cardiovasc Interv,2007,69(6):910-919.
[5]Laird JR,Yeo KK.The treatment of femoropopliteal in-stent restenosis:back to the future.J Am Coll Cardiol,2012,59(1):24-25.
[6]Bosiers M,Deloose K,Callaert J,et al.Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions.J Vasc Surg,2011,54(4):1042-1050.
[7]谷涌泉,张建,齐立行,等.动脉自膨式支架置入治疗下肢缺血.中国微创外科杂志,2006,6(11):824-826.
[8]郭建明,谷涌泉,郭连瑞,等.肝素涂层覆膜支架治疗股浅动脉硬化闭塞病变1例报告.中国微创外科杂志,2016,16(5):470-471.
[9]Werk M,Albrecht T,Meyer DR,et al.Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty.Evidence From the Randomized PACIFIER Trial.Circ Cardiovasc Interv,2012,5(6):831-840.
[10]Scheinert D,Duda S,Zeller T，et al.The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.J Am Coll Cardiol Intv,2014,7(1):10-19.
[11]Rosenfield K,Jaff MR,White CJ,et al.Trial of a Paclitaxel-coated balloon for femoropopliteal artery disease.N Engl J Med,2015,373(2):145-53.
[12]Cioppa A,Stabile E,Popusoi G,et al.Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon:one-year single centre clinical results.Cardiovasc Revasc Med,2012,13(4):219-223.
[13]Sixt S,Rastan A,Beschorner U,et al.Acute and long-term outcome of SilverHawk assisted atherectomy for femoro-popliteal lesions according the TASC II classification:a single-center experience.Vasa,2010,39(3):229-236.
[14]Zeller T,Sixt S,Schwarzwalder U,et al.Two-year results after directional atherectomy of infrapopliteal arteries with the SilverHawk device.J Endovasc Ther,2007,14(2):232-240.
[15]Farb A,Kolodgie FD,Hwang JY,et al.Extracellular matrix changes in stented human coronary arteries.Circulation,2004,110(8):940-947.
[16]Stabile E,Virga V,Salemme L，et al.Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis.J Am Coll Cardiol,2012,60(18):1739-1742.
[17]Sixt S,Carpio Cancino OG,Treszl A,et al.Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries.J Vasc Surg,2013,58(3):682-686.